



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services Are Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

Organ Rejection After Solid Organ Transplant

Based on review of available data, the Company may consider extracorporeal photopheresis (ECP) to treat cardiac allograft rejection, including acute rejection, that is either recurrent or that is refractory to standard immunosuppressive drug treatment to be **eligible for coverage.****

Graft-Versus-Host Disease

Acute

Based on review of available data, the Company may consider extracorporeal photopheresis (ECP) as a technique to treat acute graft-versus-host disease (GVHD) that is refractory to medical therapy to be **eligible for coverage.****

Chronic

Based on review of available data, the Company may consider extracorporeal photopheresis (ECP) as a technique to treat chronic graft-versus-host disease (GVHD) that is refractory to medical therapy to be **eligible for coverage.****

Cutaneous T-Cell Lymphoma

Based on review of available data, the Company may consider extracorporeal photopheresis (ECP) as a technique to treat late stage (III/IV) cutaneous T-cell lymphoma (CTCL) to be **eligible for coverage.****

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

Based on review of available data, the Company may consider extracorporeal photopheresis (ECP) as a technique to treat early stage (I/II) cutaneous T-cell lymphoma (CTCL) that is progressive and refractory to established nonsystemic therapies to be **eligible for coverage.****

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Organ Rejection After Solid Organ Transplant

Based on review of available data, the Company considers extracorporeal photopheresis (ECP) in all other situations related to treatment or prevention of rejection in solid-organ transplantation to be **investigational.***

Graft-Versus-Host Disease

Acute

Based on review of available data, the Company considers extracorporeal photopheresis (ECP) as a technique to treat acute graft-versus-host disease (GVHD) that is either previously untreated or is responding to established therapies to be **investigational.***

Chronic

Based on review of available data, the Company considers extracorporeal photopheresis (ECP) as a technique to treat chronic graft-versus-host disease (GVHD) that is either previously untreated or is responding to established therapies to be **investigational.***

Autoimmune Diseases

Based on review of available data, the Company considers extracorporeal photopheresis (ECP) as a technique to treat either the cutaneous or visceral manifestations of autoimmune diseases, including but not limited to scleroderma, systemic lupus erythematosus, rheumatoid arthritis, pemphigus, psoriasis, multiple sclerosis, diabetes, autoimmune bullous disorders, severe atopic dermatitis, or Crohn disease to be **investigational.***

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

Cutaneous T-Cell Lymphoma

Based on review of available data, the Company considers extracorporeal photopheresis (ECP) as a technique to treat early stage (I/II) cutaneous T-cell lymphoma (CTCL) that is either previously untreated or is responding to established nonsystemic therapies to be **investigational**.*

Other

Based on review of available data, the Company considers extracorporeal photopheresis (ECP) for all other indications to be **investigational**.*

Policy Guidelines

Organ Rejection After Solid Organ Transplant

A regimen of immunosuppressive therapy is standard of care for the treatment of solid organ rejection. Therefore, refractory rejection is defined as rejection that fails to respond adequately to a standard regimen of immunosuppressive therapy.

Recurrent allograft rejection is defined as having at least 2 rejection episodes after standard immunosuppressive therapy.

There is no standard schedule for extracorporeal photopheresis (ECP), and reported schedules vary by the organ type. However, most reported cardiac and lung schedules initiate therapy with 2 consecutive days of ECP in month 1, followed by biweekly therapy on 2 consecutive days in months 2 and 3, then monthly on 2 consecutive days in months 4 through 6.

Graft-Versus-Host Disease

Methylprednisolone is considered first-line treatment of acute graft-versus-host disease (GVHD). For chronic GVHD, an alternating regimen of cyclosporine and prednisone is commonly used; other therapies include antithymocyte globulin, corticosteroid monotherapy, and cytotoxic immunosuppressive drugs such as procarbazine, cyclophosphamide, or azathioprine. Therefore, refractory disease is defined as GVHD that fails to respond adequately to a trial of any of these therapies.

Treatment schedule and duration of ECP for GVHD have not been optimally defined. Guidelines and consensus statements have generally recommended 1 cycle (ie, ECP on 2 consecutive days)

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

weekly for acute GVHD and every 2 weeks for chronic GVHD. Treatment duration is based on clinical response; discontinuation is generally recommended for no or minimal response.

Cutaneous T-Cell Lymphoma Staging

Cutaneous T-cell Lymphoma staging is based on the tumor, node, metastases (TNM) classification system (see Table PG1).

Table PG1. Cutaneous T-cell Lymphoma Staging

Stage	Tumor T, N, and M Categories
IA	T1N0M0
IB	T2N0M0
IIA	T1-2N1M1
IIB	T3N0-1M0
III	T4N0-1M0
IVA	T1-4N2-3M0
IVB	T1-4N0-3M1

Sézary Syndrome

According to the World Health Organization-European Organization for Research and Treatment of Cancer, Sézary syndrome is defined by the triad of erythroderma, generalized lymphadenopathy, and the presence of neoplastic T cells (Sézary cells) in the skin, lymph nodes, and peripheral blood. The International Society of Cutaneous Lymphomas recommends an absolute Sézary cell count of at least 1000 cells per cubic millimeter, in the presence of immunophenotypical abnormalities (CD4/CD8 ratio >10; loss of any or all of the T-cell antigens CD2, CD3, CD4, and CD5; or both), or the demonstration of a T-cell clone in the peripheral blood by molecular or cytogenetic methods.

Background/Overview

Organ Rejection Treatment After Solid Organ Transplant

The standard treatment for organ transplant rejection is immunosuppression, with the particular regimen dictated by the organ being transplanted. As organ transplantation success rates have improved, more patients are facing the morbidity and mortality associated with immunosuppressive therapies developed to prevent rejection of the transplanted organ. Immunosuppressive therapies are

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

used to lower the responsiveness of the recipient's immune system, decreasing the chance of rejection. Unfortunately, portions of the immune system responsible for the prevention of viral, fungal, and bacterial infection also are affected. This can, in turn, lead to serious infections, including opportunistic infections.

Although first approved for the treatment of cutaneous T-cell lymphoma (CTCL), extracorporeal photopheresis (ECP) has more recently been used as a supplement to conventional therapies in the area of solid organ transplantation. Reports of the successful use of ECP in human cardiac transplant recipients were published in 1992 and use in other transplant patients followed. Although the specific mechanism of action of ECP is unknown, the reinfusion of treated leukocytes seems specifically to suppress the patient's immune response to the donor organ, although maintaining the body's ability to respond to other antigens. The specificity of ECP to target the immune response to the transplanted organ allows ECP to decrease organ rejection without an increased risk of infection, common with immunosuppressive drugs.

Graft-Versus-Host Disease

Given that graft-versus-host disease (GVHD) is an immune-mediated disease, ECP can be used to treat GVHD after a prior allogeneic cell transplant. In fact, GVHD can be categorized in 2 ways: (1) as an acute disease, occurring within the first 100 days after the infusion of allogeneic cells; or (2), as a chronic disease, which develops sometime after 100 days. Acute GVHD is commonly graded from I to IV, ranging from mild disease, which is characterized by a skin rash without the involvement of the liver or gut, to grades III and IV, which are characterized by generalized erythroderma, elevated bilirubin levels, or diarrhea. Grade III acute GVHD is considered severe, and grade IV is considered life-threatening. Chronic GVHD typically presents with more diverse symptomatology resembling autoimmune diseases such as progressive systemic sclerosis, systemic lupus erythematosus, or rheumatoid arthritis. Chronic GVHD may affect the mouth, eyes, respiratory tract, musculoskeletal system, and peripheral nerves, as well as the skin, liver, or gut-the usual sites of acute GVHD.

Autoimmune Disease

The use of ECP as a treatment of autoimmune disease is based on the premise that pathogenic lymphocytes form an expanded clone of cells, which are damaged when exposed to ultraviolet light in the presence of agent 8-methoxypsoralen. It is hypothesized that the resulting damage induces a population of circulating suppressor T cells targeted against the light-damaged cells. It is further

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

hypothesized that these suppressor T cells are targeted at a component of the cell that is common to the entire clone of abnormal cells (ie, not just the light-sensitized cells), thus inducing a systemic effect. However, although scleroderma and other autoimmune diseases are associated with the presence of circulating autoantibodies, it is unknown how these antibodies are related to the pathogenesis of the disease. As discussed in this evidence review, photopheresis is not associated with consistent changes in autoantibody levels.

T-Cell Lymphoma

Cutaneous T-Cell Lymphoma

According to the National Cancer Institute, CTCL is a neoplasia of malignant T lymphocytes that initially presents as skin involvement. CTCL is extremely rare, with an estimated incidence of approximately 0.4 per 100,000 annually, but because most are low-grade malignancies with long survival, overall prevalence is much higher. Two CTCL variants, mycosis fungoides and the Sézary syndrome, account for approximately 60% and 5% of new cases of CTCL, respectively.

CTCL is included in the Revised European-American Lymphoma classification as a group of low-grade T-cell lymphomas, which should be distinguished from other T-cell lymphomas that involve the skin, such as anaplastic large cell lymphoma, peripheral T-cell lymphoma, adult T-cell leukemia/lymphoma (usually with systemic involvement), or subcutaneous panniculitis T-cell lymphoma. In addition, a number of benign or very indolent conditions can be confused with mycosis fungoides, further complicating diagnosis.

Mycosis fungoides typically progresses from an eczematous patch/plaque stage, covering less than 10% of the body surface (T1), to a plaque stage, covering 10% or more of the body surface (T2), and finally to tumors (T3) that frequently undergo necrotic ulceration. Sézary syndrome is an advanced form of mycosis fungoides with generalized erythroderma (T4) and peripheral blood involvement (B1) at presentation. The cytologic transformation from a low-grade lymphoma to a high-grade lymphoma sometimes occurs during the course of these diseases and is associated with poor prognosis. A common cause of death during the tumor phase is sepsis from *Pseudomonas aeruginosa* or *Staphylococcus aureus* caused by chronic skin infection with staphylococcus species and subsequent systemic infections.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

The natural history of mycosis fungoides is typically indolent. Symptoms may present for long periods of time (mean, 2-10 years) as waxing and waning cutaneous eruptions. The prognosis of patients with mycosis fungoides or Sézary syndrome is based on the extent of disease at presentation and its stage. Lymphadenopathy and involvement of peripheral blood and viscera increase in likelihood with worsening cutaneous involvement and define poor prognostic groups. Median survival after diagnosis varies by stage. Median survival in patients with stage IA disease exceeds 20 years, with most deaths in this group typically unrelated to mycosis fungoides. In contrast, median survival in patients with stage III or IV disease is less than 5 years; more than 50% of these patients die of their disease.

Appropriate therapy of CTCL depends on a variety of factors, including stage, the patient's overall health, and the presence of symptoms. In general, therapies can be categorized into topical and systemic treatments that include ECP. In contrast to more conventional lymphomas, CTCL is usually not curable (unless caught in its earliest stages). Thus, systemic cytotoxic chemotherapy is avoided except for advanced-stage cases. Partial or complete remission is achievable, although most patients require lifelong treatment and monitoring.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

Two photopheresis systems (Therakos; now Mallinckrodt) were approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process. Both systems are approved for use in ultraviolet-A irradiation treatment, in the presence of the photoactive drug 8-methoxypsoralen, of extracorporeally circulating leukocyte-enriched blood, in the palliative treatment of skin manifestations of CTCL, in persons who have not been responsive to other forms of treatment. The 2 systems are:

- UVAR^{®‡} XTS Photopheresis System (FDA approved in 1987).
- CELLEX^{®‡} (FDA approved in 2009).

Photoactive 8-methoxypsoralen (UVADEX^{®‡}; Therakos; now Mallinckrodt) is FDA approved for extracorporeal administration with the UVAR XTS or CELLEX Photopheresis System in the palliative treatment of the skin manifestations of CTCL unresponsive to other forms of treatment.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

The use of either Therakos photopheresis system or UVADEX for other conditions is off-label. FDA product code: LNR.

Rationale/Source

Extracorporeal photopheresis (ECP) is a leukapheresis-based immunomodulatory procedure that involves the following 3 steps: (1) the patient's blood is collected into a centrifuge system that separates the leukocyte-rich portion (buffy coat) from the rest of the blood; (2) the photosensitizer agent 8-methoxypsoralen is added to the lymphocyte fraction, which is then exposed to ultraviolet-A (320-400 nm wavelength) light at a dose of 1 to 2 J/cm²; and (3) the light-sensitized lymphocytes are reinfused into the patient. The use of ECP has been investigated for patients needing treatment for organ rejection after solid organ, transplant graft-versus-host disease (GVHD), autoimmune diseases, and T-cell lymphoma.

Graft Rejection After Solid Organ Transplant

Heart Transplant

For individuals who are heart transplant recipients who experience acute graft rejection refractory to immunosuppression who receive ECP, the evidence includes a small randomized controlled trial (RCT). The relevant outcomes are overall survival (OS), change in disease status, and treatment-related mortality and morbidity. The small RCT, while suggesting similar outcomes for ECP and corticosteroids, is insufficient to permit conclusions on the utility of ECP. Studies with more patients and longer follow-up are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are heart transplant recipients who experience recurrent and/or refractory graft rejection who receive ECP, the evidence includes a comparative study and small case series. The relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Current evidence is consistent on the beneficial effect of ECP for cardiac transplant patients with graft rejection refractory to standard therapy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who are heart transplant recipients who require prophylaxis to prevent graft rejection who receive ECP, the evidence includes a small RCT. The relevant outcomes are OS, change in

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

disease status, and treatment-related mortality and morbidity. The small randomized trial is insufficient to permit conclusions on the utility of ECP. Studies with more patients and longer follow-up are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

Lung Transplant

For individuals who are lung transplant recipients who experience acute graft rejection who receive ECP, the evidence includes a small retrospective study and small case series. The relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Current evidence is very limited and any conclusions drawn lack certainty. A prospective, randomized trial is needed specifically evaluating the treatment of patients with acute graft rejection. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who are lung transplant recipients with bronchiolitis obliterans syndrome refractory to corticosteroids who receive ECP, the evidence includes a prospective study and numerous retrospective analyses. The relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Studies have shown inconsistent results across bronchiolitis obliterans syndrome grades. Prospective, RCTs are necessary with analyses stratified by syndrome grade. The evidence is insufficient to determine the effects of the technology on health outcomes.

Liver Transplant

For individuals who are liver transplant recipients who experience graft rejection and receive ECP, the evidence includes a small nonrandomized study, a retrospective study, and a case series. The relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Current evidence does not permit conclusions on the utility of ECP in this population. There is a need for RCTs comparing immunosuppressive therapy alone with immunosuppressive therapy with ECP. The evidence is insufficient to determine the effects of the technology on health outcomes.

Kidney Transplant

For individuals who are kidney transplant recipients who experience recurrent graft rejection who receive ECP, the evidence includes a small prospective study and numerous case reports. The relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Current evidence does not permit conclusions on the effect of ECP on net health outcome. RCTs, comparing immunosuppressive therapy with immunosuppressive therapy using ECP and examining

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

histologic confirmation of treatment response, are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

Graft-Versus-Host Disease

For individuals who have acute or chronic GVHD refractory to medical treatment who receive ECP, the evidence includes systematic reviews, retrospective studies, and case series. The relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Current evidence has consistently shown that ECP reduces the incidence of GVHD that is unresponsive to standard therapy. Additionally, there is a lack of other treatment options for these patients; adverse events related to ECP are minimal; and, if there is a response to ECP, patients may be able to reduce or discontinue treatment with corticosteroids and other immunosuppressive agents. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Clinical input obtained in 2014 supported the use of ECP in patients with refractory acute GVHD.

Autoimmune Disease

For individuals who have autoimmune diseases (eg, cutaneous or visceral manifestations of autoimmune diseases including but not limited to scleroderma, systemic lupus erythematosus, rheumatoid arthritis, pemphigus, psoriasis, multiple sclerosis, diabetes, autoimmune bullous disorders, severe atopic dermatitis, and Crohn disease) who receive ECP, the evidence includes isolated RCTs, small prospective and retrospective studies, and case reports. The relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. The current literature assessing the various autoimmune diseases is not sufficiently robust to support conclusions. The evidence is insufficient to determine the effects of the technology on health outcomes.

Cutaneous T-Cell Lymphoma

For individuals who have advanced-stage (stage III or IV) CTCL who receive ECP, the evidence includes a systematic review and numerous small case series. The relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Evidence from these small case series has shown a favorable response to ECP treatment and an increase in survival in a proportion of these patients. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

For individuals who have refractory or progressive early-stage (stage I or II) CTCL who receive ECP, the evidence includes a systematic review. The relevant outcomes are OS, change in disease status, and treatment-related mortality and morbidity. Given the unfavorable prognosis for patients with early-stage CTCL that progresses on non-systemic therapies, the relative lack of adverse events with ECP compared with other systemic treatments, and the good response rates often observed with ECP, this therapy is an option for those with refractory or progressive early-stage CTCL. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

In response to requests, input was received through 2 academic medical centers and 5 Blue Distinction Centers for Transplant when this policy was under review in 2014. Respondents agreed unanimously that extracorporeal photopheresis should not be medically necessary for previously untreated acute graft-versus-host disease but should be medically necessary for acute graft-versus-host disease that is refractory to medical therapy.

Practice Guidelines and Position Statements

Graft-Versus-Host Disease

Acute GVHD

American Society of Blood and Marrow Transplantation

Evidence-based recommendations from the American Society of Blood and Marrow Transplantation (2012) advised that extracorporeal photopheresis (ECP) cannot be considered superior to horse antithymocyte globulin for the treatment of acute GVHD. This conclusion was based on older studies.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

Acute and Chronic GVHD

National Cancer Institute

In its guidelines on childhood hematopoietic cell transplantation, the National Cancer Institute listed ECP as a second-line treatment for patients with acute GVHD resistant to first-line methylprednisolone. For chronic GVHD therapy, the guidelines recommended that steroids are first-line therapy, but steroid-sparing approaches, including ECP, are being developed. In this setting, ECP has shown “some efficacy in a percentage of patients.”

T-Cell Lymphoma

National Comprehensive Cancer Network guidelines on T-cell lymphomas (v.5.2018) lists the use of ECP as a category A treatment alone or in combination with other agents as first-line systemic therapy for advanced (stages III-IV) disease, as well as for patients with either earlier stage mycosis fungoides with Sézary syndrome involvement.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

Solid Organ Transplants

Effective 2006, the Centers for Medicare & Medicaid Services (CMS) concluded that ECP is reasonable and necessary for persons with “acute cardiac allograft rejection whose disease is refractory to standard immunosuppressive drug treatment”.

Effective 2012, CMS also provided coverage for ECP for the treatment of “bronchiolitis obliterans syndrome (BOS) following lung allograft transplantation only when extracorporeal photopheresis is provided under a clinical research study” that meets certain conditions.

Graft-Versus-Host Disease

Effective 2006, CMS provided coverage of ECP for patients with chronic GVHD “whose disease is refractory to standard immunosuppressive drug treatment.”

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

Autoimmune Disorders

There are no national coverage decisions on the use of ECP for the treatment of autoimmune disease.

T-Cell Lymphoma

Effective 1988, CMS provided coverage for ECP as “palliative treatment of skin manifestations of cutaneous T-cell lymphoma that has not responded to other therapy.”

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in Table 1.

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
<i>Graft-versus-host disease</i>			
NCT00637689	Improving Outcomes Assessment in Chronic GVHD	601	Feb 2020
NCT01460914	Outcomes of Cutaneous T-Cell Lymphoma and Chronic Graft-Versus-Host Disease in Patients Treated with Extracorporeal Photopheresis	100	Oct 2050
<i>Autoimmune disorders</i>			
NCT02296346 ^a	Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis	66	Oct 2017 (suspended)
<i>T-cell lymphoma</i>			
NCT01460914	Outcomes of Cutaneous T-Cell Lymphoma and Chronic Graft-Versus-Host Disease in Patients Treated with Extracorporeal Photopheresis	100	Oct 2050

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

Unpublished			
<i>Solid organ transplants</i>			
NCT01824368	Extracorporeal Photopheresis in Liver Transplantation. Phase 2 Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression (FEC-TH)	10	Apr 2016 (completed)
<i>Graft-versus-host disease</i>			
NCT01380535 ^a	A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy With UVADEX for the Treatment of Patients With Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)	60	Mar 2017 (completed)
NCT00609609	A Randomized Phase 2 Study for the Evaluation of Extracorporeal Photopheresis (ECP) in Combination With Corticosteroids for the Initial Treatment of Acute Graft-Versus-Host Disease (GVHD)	81	Jan 2016 (completed)

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Extracorporeal Photopheresis”, 8.01.36, November, 2019.
2. Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. J Clin Apher. Apr 2006;21(1):72-77. PMID 16619230.
3. Costanzo-Nordin MR, Hubbell EA, O'Sullivan EJ, et al. Photopheresis versus corticosteroids in the therapy of heart transplant rejection. Preliminary clinical report. Circulation. Nov 1992;86(5 Suppl):II242-250. PMID 1424007.
4. Rose EA, Barr ML, Xu H, et al. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant. Jul-Aug 1992;11(4 Pt 1):746-750. PMID 1498142.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

5. Hivelin M, Siemionow M, Grimbert P, et al. Extracorporeal photopheresis: from solid organs to face transplantation. *Transpl Immunol.* Jul 2009;21(3):117-128. PMID 19409991.
6. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. *J Clin Apher.* Jun 2007;22(3):106-175. PMID 17394188.
7. Carlo WF, Pearce FB, George JF, et al. Single-center experience with extracorporeal photopheresis in pediatric heart transplantation. *J Heart Lung Transplant.* Jun 2014;33(6):624-628. PMID 24661684.
8. Kirklin JK, Brown RN, Huang ST, et al. Rejection with hemodynamic compromise: objective evidence for efficacy of photopheresis. *J Heart Lung Transplant.* Mar 2006;25(3):283-288. PMID 16507420.
9. Maccherini M, Diciolla F, Laghi Pasini F, et al. Photopheresis immunomodulation after heart transplantation. *Transplant Proc.* Feb-Mar 2001;33(1-2):1591-1594. PMID 11267432.
10. Dall'Amico R, Montini G, Murer L, et al. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection. *Int J Artif Organs.* Jan 2000;23(1):49-54. PMID 12118837.
11. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. *N Engl J Med.* Dec 10 1998;339(24):1744-1751. PMID 9845709.
12. Villanueva J, Bhorade SM, Robinson JA, et al. Extracorporeal photopheresis for the treatment of lung allograft rejection. *Ann Transplant.* Mar 2000;5(3):44-47. PMID 11233043.
13. Benden C, Speich R, Hofbauer GF, et al. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience. *Transplantation.* Dec 15 2008;86(11):1625-1627. PMID 19077900.
14. Salerno CT, Park SJ, Kreykes NS, et al. Adjuvant treatment of refractory lung transplant rejection with extracorporeal photopheresis. *J Thorac Cardiovasc Surg.* Jun 1999;117(6):1063-1069. PMID 10343253.
15. Jaksch P, Scheed A, Keplinger M, et al. A prospective interventional study on the use of extracorporeal photopheresis in patients with bronchiolitis obliterans syndrome after lung transplantation. *J Heart Lung Transplant.* Sep 2012;31(9):950-957. PMID 22884382.
16. Greer M, Dierich M, De Wall C, et al. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients. *Am J Transplant.* Apr 2013;13(4):911-918. PMID 23406373.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

17. Lucid CE, Savani BN, Engelhardt BG, et al. Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT. *Bone Marrow Transplant.* Mar 2011;46(3):426-429. PMID 20581885.
18. Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. *J Heart Lung Transplant.* Apr 2010;29(4):424-431. PMID 19853479.
19. Urbani L, Mazzoni A, Catalano G, et al. The use of extracorporeal photopheresis for allograft rejection in liver transplant recipients. *Transplant Proc.* Dec 2004;36(10):3068-3070. PMID 15686696.
20. Urbani L, Mazzoni A, De Simone P, et al. Avoiding calcineurin inhibitors in the early post-operative course in high-risk liver transplant recipients: The role of extracorporeal photopheresis. *J Clin Apher.* 2007;22(4):187-194. PMID 17294458.
21. Urbani L, Mazzoni A, Colombatto P, et al. Potential applications of extracorporeal photopheresis in liver transplantation. *Transplant Proc.* May 2008;40(4):1175-1178. PMID 18555142.
22. Jardine MJ, Bhandari S, Wyburn KR, et al. Photopheresis therapy for problematic renal allograft rejection. *J Clin Apher.* Jun 2009;24(4):161-169. PMID 19536814.
23. Kumlien G, Genberg H, Shanwell A, et al. Photopheresis for the treatment of refractory renal graft rejection. *Transplantation.* Jan 15 2005;79(1):123-125. PMID 15714180.
24. Dall'Amico R, Murer L. Extracorporeal photochemotherapy: a new therapeutic approach for allograft rejection. *Transfus Apher Sci.* Jun 2002;26(3):197-204. PMID 12126206.
25. Dall'Amico R, Murer L, Montini G, et al. Successful treatment of recurrent rejection in renal transplant patients with photopheresis. *J Am Soc Nephrol.* Jan 1998;9(1):121-127. PMID 9440096.
26. Baron ED, Heeger PS, Hricik DE, et al. Immunomodulatory effect of extracorporeal photopheresis after successful treatment of resistant renal allograft rejection. *Photodermatol Photoimmunol Photomed.* Apr 2001;17(2):79-82. PMID 11338406.
27. Sunder-Plassman G, Druml W, Steininger R, et al. Renal allograft rejection controlled by photopheresis. *Lancet.* Aug 19 1995;346(8973):506. PMID 7637500.
28. Abu-Dalle I, Reljic T, Nishihori T, et al. Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. *Biol Blood Marrow Transplant.* Nov 2014;20(11):1677-1686. PMID 24867779.
29. Flowers ME, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. *Blood.* Oct 1 2008;112(7):2667- 2674. PMID 18621929.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

30. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Extracorporeal photopheresis for graft-versus-host disease. TEC Assessments. 2001;Volume 16:Tab 9.
31. Hautmann AH, Wolff D, Hahn J, et al. Extracorporeal photopheresis in 62 patients with acute and chronic GVHD: results of treatment with the COBE Spectra System. *Bone Marrow Transplant.* Mar 2013;48(3):439-445. PMID 22922407.
32. Ussowicz M, Musial J, Mielcarek M, et al. Steroid-sparing effect of extracorporeal photopheresis in the therapy of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Transplant Proc.* Nov 2013;45(9):3375-3380. PMID 24182819.
33. Weitz M, Strahm B, Meerpohl JJ, et al. Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. *Cochrane Database Syst Rev.* 2014;2:CD009759. PMID 24569960.
34. Weitz M, Strahm B, Meerpohl JJ, et al. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. *Cochrane Database Syst Rev.* Feb 25 2014;2(2):CD009898. PMID 24569961.
35. Perotti C, Del Fante C, Tinelli C, et al. Extracorporeal photochemotherapy in graft-versus-host disease: a longitudinal study on factors influencing the response and survival in pediatric patients. *Transfusion.* Jun 2010;50(6):1359-1369. PMID 20113452.
36. Halle P, Paillard C, D'Incan M, et al. Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients. *J Hematother Stem Cell Res.* Jun 2002;11(3):501-512. PMID 12183835.
37. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. *Transfusion.* Oct 2001;41(10):1299-1305. PMID 11606832.
38. Berger M, Pessolano R, Albiani R, et al. Extracorporeal photopheresis for steroid resistant graft versus host disease in pediatric patients: a pilot single institution report. *J Pediatr Hematol Oncol.* Oct 2007;29(10):678-687. PMID 17921848.
39. Zhang H, Chen R, Cheng J, et al. Systematic review and meta-analysis of prospective studies for ECP treatment in patients with steroid-refractory acute GVHD. *Patient Prefer Adherence.* Feb 2015;9:105-111. PMID 25653504.
40. Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. *Haematologica.* Mar 2006;91(3):405-408. PMID 16531267.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

41. Jagasia M, Greinix H, Robin M, et al. Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. *Biol Blood Marrow Transplant*. Jul 2013;19(7):1129-1133. PMID 23623892.
42. Rubegni P, Feci L, Poggiali S, et al. Extracorporeal photopheresis: a useful therapy for patients with steroid- refractory acute graft-versus-host disease but not for the prevention of the chronic form. *Br J Dermatol*. Aug 2013;169(2):450-457. PMID 23534380.
43. Shaughnessy PJ, Bolwell BJ, van Besien K, et al. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant*. Jun 2010;45(6):1068-1076. PMID 19915634.
44. Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. *Bone Marrow Transplant*. Nov 2008;42(9):609-617. PMID 18660840.
45. Malik MI, Litzow M, Hogan W, et al. Extracorporeal photopheresis for chronic graft-versus-host disease: a systematic review and meta-analysis. *Blood Res*. Jun 2014;49(2):100-106. PMID 25025011.
46. Ontario Health Technology Advisory Committee. OHTAC Recommendation: Extracorporeal Photopheresis. 2006; http://www.hqontario.ca/english/providers/program/ohtac/tech/recommend/rec_ecp_032806.pdf.
47. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. *Bone Marrow Transplant*. Jun 2005;35(12):1187-1193. PMID 15852025.
48. Dignan FL, Aguilar S, Scarisbrick JJ, et al. Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. *Bone Marrow Transplant*. May 2014;49(5):704-708. PMID 24566709.
49. Greinix HT, Volc-Platzer B, Knobler R. Criteria for assessing chronic GVHD. *Bone Marrow Transplant*. Mar 2000;25(5):575. PMID 10713639.
50. Rubegni P, Cuccia A, Sbano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease. *Br J Haematol*. Jul 2005;130(2):271-275. PMID 16029456.
51. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Extracorporeal photopheresis for autoimmune disease. TEC Assessments. 2001;Volume 16:Tab 10.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

52. Rook AH, Freundlich B, Jegasothy BV, et al. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. *Arch Dermatol*. Mar 1992;128(3):337-346. PMID 1550365.
53. Fries JF, Seibold JR, Medsger TA, Jr. Photopheresis for scleroderma? No! *J Rheumatol*. Jul 1992;19(7):1011- 1013. PMID 1512753.
54. Melski JW. Price of technology. A blind spot. *JAMA*. Mar 18 1992;267(11):1516-1518. PMID 1538542.
55. Trentham DE. Photochemotherapy in systemic sclerosis. The stage is set. *Arch Dermatol*. Mar 1992;128(3):389- 390. PMID 1550373.
56. Papp G, Horvath IF, Barath S, et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. *Clin Immunol*. Feb 2012;142(2):150-159. PMID 22036269.
57. Cavaletti G, Perseghin P, Dassi M, et al. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. *Neurol Sci*. Apr 2006;27(1):24- 32. PMID 16688596.
58. Ludvigsson J, Samuelsson U, Ernerudh J, et al. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. *Arch Dis Child*. Aug 2001;85(2):149-154. PMID 11466190.
59. Sanli H, Akay BN, Ayyildiz E, et al. Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy. *Transfus Apher Sci*. Dec 2010;43(3):353-359. PMID 21035398.
60. Rubegni P, Poggiali S, Cevenini G, et al. Long term follow-up results on severe recalcitrant atopic dermatitis treated with extracorporeal photochemotherapy. *J Eur Acad Dermatol Venereol*. Apr 2013;27(4):523-526. PMID 22540319.
61. Wolf P, Georgas D, Tomi NS, et al. Extracorporeal photochemotherapy as systemic monotherapy of severe, refractory atopic dermatitis: results from a prospective trial. *Photochem Photobiol Sci*. Jan 2013;12(1):174-181. PMID 22948099.
62. Reinisch W, Knobler R, Rutgeerts PJ, et al. Extracorporeal photopheresis (ECP) in patients with steroid- dependent Crohn's disease: an open-label, multicenter, prospective trial. *Inflamm Bowel Dis*. Feb 2013;19(2):293-300. PMID 22573600.
63. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. *N Engl J Med*. Feb 5 1987;316(6):297-303. PMID 3543674.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

64. Knobler R, Duvic M, Querfeld C, et al. Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. *Photodermatol Photoimmunol Photomed*. Oct 2012;28(5):250-257. PMID 22971190.
65. Freiman A, Sasseville D. Treatment of mycosis fungoides: overview. *J Cutan Med Surg*. Sep-Oct 2006;10(5):228-233. PMID 17234106.
66. Keehn CA, Belongie IP, Shistik G, et al. The diagnosis, staging, and treatment options for mycosis fungoides. *Cancer Control*. Apr 2007;14(2):102-111. PMID 17387295.
67. Knobler E. Current management strategies for cutaneous T-cell lymphoma. *Clin Dermatol*. May-Jun 2004;22(3):197-208. PMID 15262305.
68. Scarisbrick JJ. Staging and management of cutaneous T-cell lymphoma. *Clin Exp Dermatol*. Mar 2006;31(2):181-186. PMID 16487086.
69. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. *Cancer Treat Rev*. Apr 2007;33(2):146-160. PMID 17275192.
70. Scarisbrick JJ, Taylor P, Holtick U, et al. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. *Br J Dermatol*. Apr 2008;158(4):659-678. PMID 18241274.
71. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. *Eur J Cancer*. May 2006;42(8):1014-1030. PMID 16574401.
72. Whittaker SJ, Marsden JR, Spittle M, et al. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. *Br J Dermatol*. Dec 2003;149(6):1095-1107. PMID 14696593.
73. National Cancer Institute. Mycosis Fungoides (Including Sezary Syndrome) Treatment (PDQ) Health Professional Version. 2018; <https://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq?redirect=true>.
74. Miller JD, Kirkland EB, Domingo DS, et al. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma. *Photodermatol Photoimmunol Photomed*. Oct 2007;23(5):163-171. PMID 17803594.
75. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. *Blood*. May 15 2005;105(10):3768-3785. PMID 15692063.
76. Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. Aug 2012;18(8):1150-1163. PMID 22510384.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

- 77. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft- versus-host disease after haematopoietic stem cell transplantation. Br J Haematol. Jul 2003;122(1):118-127. PMID 12823353.
- 78. National Cancer Institute. Childhood Hematopoietic Cell Transplantation (PDQ<ae>)<ad>Health Professional Version. 2018; <https://www.cancer.gov/types/childhood-cancers/child-hct-hp-pdq#section/all?redirect=true>.
- 79. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines on oncology: T-cell lymphomas. Version 5.2018. https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf.
- 80. Center for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for Extracorporeal Photopheresis (110.4). 2012; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=113&ncdver=3&bc=AAAAgAAAAAAAAAA%3d%3d&>.

Policy History

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

- 05/14/2002 Medical Director review
- 05/16/2002 Medical Policy Committee review
- 06/05/2002 Managed Care Advisory Council approval
- 06/24/2002 Format revision. No substance change to policy
- 06/01/2004 Medical Director review
- 06/15/2004 Medical Policy Committee review. Format revision. No substance change to policy
- 06/28/2004 Managed Care Advisory Council approval
- 07/12/2006 Medical Director review
- 07/19/2006 Medical Policy Committee review. Format revision. No change to policy guidelines.
- 11/07/2007 Medical Director review
- 11/15/2007 Medical Policy Committee approval. No change to coverage eligibility.
- 11/05/2008 Medical Director review
- 11/18/2008 Medical Policy Committee approval. No change to coverage eligibility.
- 12/04/2009 Medical Policy Committee approval.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

- 12/16/2009 Medical Policy Implementation Committee approval. Policy title revised to reflect cutaneous T-cell lymphoma (CTCL) indication. Three new policy statements for CTCL added.
- 12/01/2010 Medical Policy Committee approval.
- 12/15/2010 Medical Policy Implementation Committee approval. No change to coverage.
- 12/08/2011 Medical Policy Committee review
- 12/21/2011 Medical Policy Implementation Committee approval. Changed title from “Extracorporeal Photopheresis after Solid-Organ Transplant and for Graft-versus-Host Disease, Autoimmune Disease, and Cutaneous T-Cell Lymphoma” to “Extracorporeal Photopheresis after Solid-Organ Transplant and for Graft-versus-Host Disease, Autoimmune Disease, and Cutaneous T-Cell Lymphoma”. Added coverage statement for extracorporeal photopheresis to treat cardiac allograft rejection, including acute rejection, that is either recurrent or that is refractory to standard immunosuppressive drug treatment. Extracorporeal photopheresis in all other situations related to treatment or prevention of rejection in solid-organ transplantation added as investigational. Autoimmune bullous disorders added as investigational. Updated coverage guidelines, Background/Overview, Rationale, and References.
- 12/06/2012 Medical Policy Committee review
- 12/19/2012 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
- 12/12/2013 Medical Policy Committee review
- 12/18/2013 Medical Policy Implementation Committee approval. Title changed from “Extracorporeal Photopheresis after Solid-Organ Transplant and for Graft-versus-Host Disease, Autoimmune Disease, and Cutaneous T-Cell Lymphoma” to “Extracorporeal Photopheresis”. Statement added that extracorporeal photopheresis is investigational for any other indications.
- 03/05/2015 Medical Policy Committee review
- 03/20/2015 Medical Policy Implementation Committee approval. Coverage eligibility updated, added coverage of acute GVHD. Rationale and references updated.
- 08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
- 03/03/2016 Medical Policy Committee review

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

03/16/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

10/01/2016 Coding update

01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes

03/02/2017 Medical Policy Committee review

03/15/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

03/01/2018 Medical Policy Committee review

03/21/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

03/07/2019 Medical Policy Committee review

03/20/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

03/05/2020 Medical Policy Committee review

03/11/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

09/10/2020 Coding update

Next Scheduled Review Date: 03/2021

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2019 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	36522
HCPCS	No codes
ICD-10 Diagnosis	A00.0, C84.00-C84.09, C84.40-C84.49, D59.0, D89.82-D89.89, E06.3, E10.10-E10.11, E10.40-E10.49, E10.610, E10.641, E10.65, E10.69, E10.8-E10.9, E11.00-E11.01, E11.40-E11.49, E11.610, E11.641, E11.65, E11.69, E11.8-E11.9, E13.00-E13.01, E13.10-E13.11, E13.40-E13.49, E13.610, E13.641, E13.8-E13.9, E20.0, E20.8-E20.9, G35, G51.0, G56.00-G56.02, I89.0, I97.2, K12.1-K12.2, K12.30, K12.39, L10.0-L10.5, L10.81, L10.89, L10.9, L11.0, L40.0-L40.9, L85.0-L85.2, L86, L87.0, L87.2, M05.00, M05.011-M05.079, M05.09, M05.20, M05.211-M05.279, M05.29-M05.30, M05.311-M05.379, M05.39-M05.40, M05.411-M05.479, M05.49-M05.50, M05.511-M05.579, M05.59-M05.60, M05.611-M05.679, M05.69-M05.70, M05.711-M05.779, M05.79-M05.80, M05.811-M05.879, M05.89-M05.9, M06.00, M06.011-M06.079, M06.08-M06.09, M06.1, M06.20, M06.211-M06.279, M06.28-M06.30, M06.311-M06.379, M06.38-M06.4, M06.80, M06.811-M06.879, M06.88-M06.9, M08.00, M08.011-M08.079, M08.08-M08.09, M08.20, M08.211-M08.279, M08.28-M08.29, M08.3, M08.40, M08.411-M08.479, M08.48, M08.80, M08.811-M08.879, M08.88-M08.90, M08.911-M08.879, M08.98-M08.99, M24.9, M25.521-M25.569, M25.711-M25.719, M26.60-M26.69, M26.601-M26.609, M26.611-M26.619, M26.621-M26.629, M26.631-M26.639, M32.0, M32.10-M32.19,

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

	<p>M32.8-M32.9, M34.0-M34.2, M34.81-M34.89, M34.9, M35.00-M35.09, M54.5, M72.2, M75.00-M75.02, M75.30-M75.32, M75.40-M75.42, M75.80-M75.82, M75.90-M75.92, M77.9, R29.898, T86.00-T86.23, T86.290, T86.298, T86.30-T86.49, T86.810-T86.819, T86.90-T86.9</p> <p>Deleted code eff 10/1/2020: D59.1</p> <p>Added codes eff 10/1/2020: D59.10-D59.19, D89.831-D89.839, M05.7A, M05.8A, M06.0A, M06.8A, M08.0A, M08.2A, M08.4A, M08.9A, M24.19, M24.29, M24.39, M24.49, M24.59, M24.69, M24.89, M25.39, M25.59, M25.69, M26.641-M26.649, M26.651-M26.659, T86.8401-T86.8409, T86.8411-T86.8419, T86.8421-T86.8429, T86.8481-T86.8489, T86.8491-T86.8499,</p>
--	--

***Investigational –** A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

****Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment,

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Extracorporeal Photopheresis

Policy # 00099

Original Effective Date: 06/05/2002

Current Effective Date: 04/13/2020

would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.